Hematologic diseases encompass a wide range of disorders affecting the blood and blood-forming organs, ranging from relatively benign conditions such as anemia, to more severe cancers of the blood. Common hematologic tumors include leukemia, lymphoma and multiple myeloma, which are characterized by the abnormal proliferation of blood cells or lymphatic tissue. These conditions necessitate specialized treatment approaches, such as chemotherapy, immunotherapy (including cellular immunotherapy), and hematopoietic cell transplantation. Timely diagnosis and tailored treatment are crucial for effectively managing these intricate hematologic diseases .Early diagnosis and personalized treatment plans are crucial for managing these complex hematologic diseases effectively.
GoBroad Healthcare Group (GHG) is a pioneer of the research-oriented hospital mode in China. We are trusted specialists in diagnosing and treating complex and serious hematologic diseases, dedicated to committed to providing high-quality, state-of-the-art healthcare at every stage of cancer treatment. Our medical services include:
- Focusing on the diagnosis and treatment of difficult and severe Hematologic Diseases such as leukemia, lymphoma, multiple myeloma, and thalassemia.
- Providing accurate diagnosis and individualized treatment. Individualizing the diagnosis and treatment plan for each patient by an effective combination of chemotherapy, radiotherapy, immunotherapy, targeted therapy, hematopoietic stem cell transplant and other technologies.
- Expanding the clinical application and research of CAR-T, innovative drugs and other advanced technologies to obtain more treatment options for refractory and relapsed patients.
- Safeguarding the whole treatment period for patients through efficient collaboration of the multidisciplinary team.
Myeloma
Thalassemia
Rare Diseases
Leukemia
Lymphoma
Myeloma
Thalassemia
Rare Diseases
Leukemia
Lymphoma
Myeloma
We offer the following cutting-edge therapies for relapsed or refractory multiple myeloma, which are typically successful in relieving even the drug-resistant cases. Usually, these therapies are effective in relieving even the most resistant cases.
1. Novel drug therapy with different mechanisms for relapsed/refractory multiple myeloma.
2. CAR-T treatment for multiple myeloma.
3. Hematologic stem cell transplantation (HSCT) for multiple myeloma.
4. Consolidation therapy with CAR-T therapy followed by allo-HSCT for refractory multiple myeloma/secondary plasma cell leukemia.
Our treatment for thalassemia major provides effective options for patients with thalassemia. These options include:
1. Double-insurance Dual HSCT (DD-HSCT) for thalassemia, with a 4-year disease-free survival rate (DFS) of 97.6%.
2. TCRαβ+T Cell Depleted HCT (TDH) for thalassemia.
As one of the best hospitals for stem cell transplants, we also focus on the treatment of rare blood diseases. We have innovative treatment technologies in the following fields:
1. The world's first case treated with allo-HSCT for rare immune deficiency disease–Lysine-urine protein intolerance (LPI).
2. Allo-HSCT for X-linked agammaglobulinemia.
3. Allo-HSCT for chronic granulomatous disease (CGD).
4. Allo-HSCT for Wiskott-Aldrich syndrome (WAS).
5. Allo-HSCT for severe combined immunodeficiency (SCID). 6. Allo-HSCT for hemophagocytic lymphohistiocytosis (HLH).
We provide a variety of advanced treatments for leukemia, a type of blood disease. These therapies provide comprehensive and thorough cancer treatment for leukemia patients across all age groups.
1. Single-target CAR-T therapy targeting CD19, CD20, CD22, CD7, CD5, GPRC5D, CLL1.
2. Sequential dual-target CAR-T cell therapy for refractory/relapsed acute leukemia.
3. Hematologic stem cell transplantation (HSCT) for refractory/relapsed acute leukemia,ranging from 1 month to 74 years old. Thousands of cases completed cumulatively, exploring innovative transplantation methods with high success rates and low complication rates.
4. Combined treatment of CAR-T therapy with chemotherapy, targeted therapy, or allogeneic hematopoietic stem cell transplantation (allo-HSCT) for refractory/relapsed acute leukemia.
For refractory or recurrent lymphoma, we provide various treatment options for both B-cell and T-cell lymphomas, which include:
1. Risk stratification and precise targeted therapy guided by NGS, and optimized CAR-T cell therapy based on high-risk molecular genetic backgrounds.
2. CAR-T therapy targeting different single antigens,dual-target CAR-T therapy,sequential CAR-T therapy for refractory/relapsed lymphoma.
3. CAR-T combined with autologous hematopoietic stem cell transplantation (auto-HSCT) , allogeneic hematopoietic stem cell transplantation (allo-HSCT) for refractory/relapsed lymphoma.
4. Donor-derived CAR-T therapy bridging to allo-HSCT for refractory/relapsed lymphoma.
We offer the following cutting-edge therapies for relapsed or refractory multiple myeloma, which are typically successful in relieving even the drug-resistant cases. Usually, these therapies are effective in relieving even the most resistant cases.
1. Novel drug therapy with different mechanisms for relapsed/refractory multiple myeloma.
2. CAR-T treatment for multiple myeloma.
3. Hematologic stem cell transplantation (HSCT) for multiple myeloma.
4. Consolidation therapy with CAR-T therapy followed by allo-HSCT for refractory multiple myeloma/secondary plasma cell leukemia.
Our treatment for thalassemia major provides effective options for patients with thalassemia. These options include:
1. Double-insurance Dual HSCT (DD-HSCT) for thalassemia, with a 4-year disease-free survival rate (DFS) of 97.6%.
2. TCRαβ+T Cell Depleted HCT (TDH) for thalassemia.
As one of the best hospitals for stem cell transplants, we also focus on the treatment of rare blood diseases. We have innovative treatment technologies in the following fields:
1. The world's first case treated with allo-HSCT for rare immune deficiency disease–Lysine-urine protein intolerance (LPI).
2. Allo-HSCT for X-linked agammaglobulinemia.
3. Allo-HSCT for chronic granulomatous disease (CGD).
4. Allo-HSCT for Wiskott-Aldrich syndrome (WAS).
5. Allo-HSCT for severe combined immunodeficiency (SCID). 6. Allo-HSCT for hemophagocytic lymphohistiocytosis (HLH).
We provide a variety of advanced treatments for leukemia, a type of blood disease. These therapies provide comprehensive and thorough cancer treatment for leukemia patients across all age groups.
1. Single-target CAR-T therapy targeting CD19, CD20, CD22, CD7, CD5, GPRC5D, CLL1.
2. Sequential dual-target CAR-T cell therapy for refractory/relapsed acute leukemia.
3. Hematologic stem cell transplantation (HSCT) for refractory/relapsed acute leukemia,ranging from 1 month to 74 years old. Thousands of cases completed cumulatively, exploring innovative transplantation methods with high success rates and low complication rates.
4. Combined treatment of CAR-T therapy with chemotherapy, targeted therapy, or allogeneic hematopoietic stem cell transplantation (allo-HSCT) for refractory/relapsed acute leukemia.
For refractory or recurrent lymphoma, we provide various treatment options for both B-cell and T-cell lymphomas, which include:
1. Risk stratification and precise targeted therapy guided by NGS, and optimized CAR-T cell therapy based on high-risk molecular genetic backgrounds.
2. CAR-T therapy targeting different single antigens,dual-target CAR-T therapy,sequential CAR-T therapy for refractory/relapsed lymphoma.
3. CAR-T combined with autologous hematopoietic stem cell transplantation (auto-HSCT) , allogeneic hematopoietic stem cell transplantation (allo-HSCT) for refractory/relapsed lymphoma.
4. Donor-derived CAR-T therapy bridging to allo-HSCT for refractory/relapsed lymphoma.
We offer the following cutting-edge therapies for relapsed or refractory multiple myeloma, which are typically successful in relieving even the drug-resistant cases. Usually, these therapies are effective in relieving even the most resistant cases.
1. Novel drug therapy with different mechanisms for relapsed/refractory multiple myeloma.
2. CAR-T treatment for multiple myeloma.
3. Hematologic stem cell transplantation (HSCT) for multiple myeloma.
4. Consolidation therapy with CAR-T therapy followed by allo-HSCT for refractory multiple myeloma/secondary plasma cell leukemia.
